Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 527
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jakesz, R. Search for Related Content PubMed Articles by Jakesz, R.

Abstract

Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)

Vienna Gen Hosp, Vienna, Austria; Graz Univ, Graz, Austria; Salzburg Hosp, Salzburg, Austria; Wiener Neustadt Hosp, Wiener Neustadt, Austria; Vienna Univ, Vienna, Austria; BHS Hosp Linz, Linz, Austria; Hanusch Medcl Ctr, Vienna, Austria

527

Background: ABCSG Trial 6 demonstrated that postmenopausal women with pT1–3a, any N, M0 hormone receptor-positive early stage breast cancer (EBC) randomized to 2 years tamoxifen (TAM) in combination with aminoglutethimide (AG) 500 mg, followed by 3 years TAM (n=996), did not have an improved prognosis, when compared with patients treated with 5 years TAM (n=990). We present results from ABCSG-6a, an extended adjuvant trial of ABCSG-6, which investigates whether continuing treatment with anastrozole (‘Arimidex’) [ANA] will improve overall prognosis. Methods: Postmenopausal women who had received TAM in combination with AG (n=406), or TAM alone (n=450), were re-randomized to switch to ANA 1 mg/day or no treatment (NT) for a further 3 years. The primary endpoint was event-free survival. Local or regional relapse was confirmed histologically where possible. Differences between the treatment groups were assessed by log-rank test. Results: Tumors <1cm,1–2 cm, or > 2cm in diameter were found in 135, 402 and 319 patients, respectively. Of the 856 patients, 578 had N0 disease, 261 patients had 1–3 nodes and 17 patients had >4 nodes involved. 171 patients had a histological Grade 3 lesion and 685 patients had Grade 1, 2 or lobular carcinomas. At 5 years’ median follow-up, 86 patients experienced local regional, distant metastases or contralateral breast cancer. Significantly fewer patients in the ANA group experienced disease recurrence compared with the NT group (30 vs 56 patients, respectively; hazard ratio 0.64; 95% confidence interval 0.41, 0.99; p=0.047). There was no statistically significant difference with respect to overall survival. Conclusions: Significantly fewer patients receiving ANA experienced disease relapse compared with placebo following 5 years of TAM with or without AG in postmenopausal women with EBC. Our results show that postmenopausal women who have completed 5 years of therapy with TAM with or without AG benefit from extended adjuvant therapy with ANA.

No significant financial relationships to disclose.

Abstract presentation from the 2005 ASCO Annual Meeting